EUCTR2017-002853-13-DE进行中（未招募）1 期
Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab(EWALL-BOLD) - EWALL-BOLD
Goethe Universität Frankfurt0 个研究点目标入组 30 人开始时间: 2017年10月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Newly diagnosed patients with CD19 positive B–precursor ALL
- •2. Greater than 25% blasts in the bone marrow
- •3. Eastern Cooperative Oncology Group (ECOG) performance status = 2
- •4. Charlson comorbidity score = 2
- •5. Age >55 and <75 years at the time of informed consent*
- •6. Renal and hepatic function as defined below:
- •- AST (SGOT), ALT (SGPT), and AP < 5 x upper limit of normal (ULN) (unless related to leukemic liver infiltration by investigator assessment)”
- •- Total bilirubin < 1.5 x ULN (unless related to Gilbert's Meulengracht disease)
- •- Creatinine < 1.5x ULN
- •- Creatinine clearance > 50 mL/min (e.g. calculated according Cockroft & Gault)
- •7. Negative pregnancy test in women of childbearing potential
- •8. Ability to understand and willingness to sign a written informed
- •9. For Germany: Participation in the registry of the German Multicenter Study Group for Adult ALL (GMALL)
- •* in patients aged 75-76 years fulfilling all inclusion criteria without exclusion criteria and without relevant comorbidities the decision on inclusion can be discussed on an individual basis with the study coordination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1. Antileukemic pretreatment (GMALL prephase with dexamethasone and cyclophosphamide allowed)
- •2. History of malignancy other than ALL within 5 years prior to start of protocol-specified therapy with the exception of:
- •- Malignancy treated with curative intent and with no known active disease present for 2 years before enrollment and felt to be at low risk for recurrence by the treating physician including
- •- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •- Adequately treated cervical carcinoma in situ without evidence of disease
- •- Adequately treated breast ductal carcinoma in situ without evidence of disease
- •- Prostatic intraepithelial neoplasia without evidence of prostate cancer.
- •3. History or presence of clinically relevant (per investigator's assessment) CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson’s disease, cerebellar disease, organic brain syndrome, or psychosis
- •4. Active ALL in the CNS (confirmed by CSF analysis) or testes (clinical diagnosis) or other extramedullary involvement; non-bulky lymph node (< 7.5 cm diameter) involvement will be accepted.
- •5. Current autoimmune disease or history of autoimmune disease with potential CNS involvement
- •6. Known exclusion criteria to recommended chemotherapy
- •7. Known positivity of HIV, hepatitis B (HbsAG) or hepatitis C virus (anti-HCV)
- •8. Subject received prior anti-CD19 therapy
- •9. Live vaccination within 2 weeks before the start of study treatment
- •10. Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation
- •- Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study(s). Thirty days is calculated from day 1 of protocol-specified therapy
- •- Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
- •- Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject and Investigator’s knowledge.
- •- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
- •- Woman of childbearing potential and is not willing to use a highly effective method of contraception while receiving study treatment and for an additional 3 months after the last dose of study treatment.
- •- Male who has a female partner of childbearing potential, and is not willing to use 2 highly effective forms of contraception while receiving protocol-specified therapy and for at least an additional 3 months after the last dose of protocol-specified therapy
研究者
相似试验
招募中
不适用
Phase II, randomized, double-blind clinical trial for efficacy of Granulocyte-colony stimulating factor(G-CSF) and autologous cord blood infusion in children with cerebral palsyKCT0002512Hanyang University Seoul Hospital98
进行中（未招募）
1 期
Clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with phosphomannomutase deficiency.Cerebellar syndromeMedDRA version: 19.1Level: PTClassification code 10008072Term: Cerebellar syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-000810-44-ESFundació Sant Joan de Déu30
进行中（未招募）
1 期
Clinical Trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19.EUCTR2020-001450-22-ESFundación de Investigación del Hospital Infantil Universitario Niño Jesús106
进行中（未招募）
1 期
Phase II clinical trial evaluating the efficacy of PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) or de novo relapsed or refractory AMMyeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherapy associated aplasiaMedDRA version: 17.1Level: LLTClassification code 10066572Term: AML progressionSystem Organ Class: 100000004864EUCTR2014-002752-50-FRINSTITUT CURIE
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25